purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation dvax earnings call period ending december image source motley fool dynavax technology dvax q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorgood day lady gentleman welcome dynavax technology fourth quarter full year financial result conference call reminder call recorded end company prepared remark open call question provide specific instruction time would like turn call paul cox vice president investor relation corporate communication may begin paul cox vice president investor relation corporate communication thank participating today call joining dynavax ryan spencer chief executive officer donn casale chief commercial officer rob janssen chief medical officer kelly macdonald chief financial officer earlier today dynavax released financial result fourth quarter full year ended december st copy press release supplementary slide presentation available dynavaxs website begin advise making forwardlooking statement today based current expectation belief including limited potential market size market segmentation effective marketing effort future expected market share related growth rate related acip recommendation impact financial guidance trend including revenue profitability cash flow sufficiency current capitalization timing result fda submission clinical trial start data readout potential future us demand cpg adjuvant statement involve risk uncertainty actual result may differ materially risk summarized today press release detailed risk factor section sec filing including today annual report form k forwardlooking statement speak today undertake obligation update statementsand turn call ryan ryan spencer chief executive officer thanks paul good afternoon everyone thank taking time join u review dynavaxs result characterized record revenue growth heplisavb delivering growth year year becoming market share leader two largest growth segment retail pharmacy integrated delivery network making heplisavb leading vaccine u adult hepatitis b vaccine market expect important year building vaccine portfolio bestinclass product including growing heplisavb brand advancing pipeline program clinical trial initiation data readout heplisavb forecasting continued growth net product revenue range million million year minute donn provide additional commentary u hepatitis b vaccine market evolving due active winter respiratory disease season continue confident another year growth brand longterm prospect heplisavb vaccine market one largest total addressable population united state development pipeline expect achieve important milestone coming month including pdufa action date heplisavb sbla hemodialysis expected may clearing shingle ind currently reviewed fda begin phase trial advancing tdap program delivering phase clinical nonhuman primate challenge study data plague program collaboration u department defense importantly strong financial position million cash provides u optionality continue build value across business incremental investment drive heplisavb market opportunity continuing advance rd effort pursuing new opportunity accelerate growth discussed previously continue evaluate strategic opportunity diversify clinical commercial product portfolio remain committed disciplined capital allocation generate significant value accelerate growth look forward providing update effort future turn call donn provide detail heplisavb result guidance looking forward donn casale senior vice president commercial thank ryan achieved record net product sale market share establishing heplisavb leading adult hepatitis b vaccine u market additionally drove significant hepatitis b market growth effectively pulling acip universal recommendation success reaffirms confidence sizable market opportunity longterm revenue growth potential heplisavb u adult hepatitis market continued grow following acip universal recommendation hepatis b vaccination represents one largest vaccine market opportunity adult believe recommendation continue significant catalyst growth estimate hepatitis b vaccine market opportunity heplisav grew approximately million clear path approximately million heplisavb achieving majority market share time fourth quarter continued see indicator u market expansion acip universal recommendation despite softness market related reduced wellness visit increased focus healthcare provider respiratory disease vaccine including typical flu campaign launch rsv endemic covid vaccine heplisavb continues increase total u market share achieving end compared end net product revenue grew year year sale growth continues driven heplisavb strong performance two critical segment retail pharmacy integrated delivery network idn continue focus sale marketing effort retail pharmacy idn segment expect see anticipated market growth acip universal recommendation segment estimating grow represent total hepatitis b market heplisavb market share leader key segment idns end year heplisavb market share increased approximately compared approximately end focused working large health system csuite clinic level pull ongoing adoption universal recommendation customer continue respond positively acip change recognize need adopt implement recommendation full year hepatitis b vaccine market growth idn segment retail pharmacy segment made significant progress several large national chain making heplisavb preferred adult hepatitis b vaccine end year heplisav achieved approximately market share retail pharmacy segment compared approximately end continue see expect significant growth retail pharmacy segment full year hepatitis b vaccine market growth ryan noted providing full year net product revenue guidance heplisavb range million million guidance reflects momentum market factoring evolving market landscape emerging quarterly pattern nonrespiratory vaccination expect see based feedback customer cough cold flu season extended much january expected reducing number wellness visit vaccination opportunity due softness january anticipate little growth hepatitis b vaccine market q compared q encouragingly expect market strengthen remainder q q focus healthcare provider retail pharmacy shifted back prioritizing nonrespiratory vaccine result expect recognize full year revenue range second third quarter typical q seasonality expected extremely confident longterm expansion u hepatitis b vaccine market forecast annual market growth approximately next several year heplisavb gaining meaningful increase total market share time summary tremendous reaffirming confidence heplisavb strengthen position clear market leader expanding hepatitis b vaccine market proud commercial team execution encouraged progress momentum heplisavb establishing majority market share key segment retail pharmacy idn turn call rob take clinical pipelinerobert janssen chief medical officer thank donn reminder development pipeline advancing innovative diversified vaccine leverage cpg adjuvant proven antigen also continue identify new opportunity leverage cpg adjuvant multiple innovative preclinical discovery effort leading collaborator starting shingle vaccine program z currently successful licensed vaccine market believe opportunity develop improved vaccine given challenging tolerability profile current marketleading product one unique advantage believe cpg adjuvant safety tolerability profile combined ability induce strong cd positive cell response believe critical preventing reactivation disaster virus result phase trial support continued development z demonstrate opportunity develop shingle vaccine improved tolerability profile comparable efficacy late last year received type b meeting feedback fda z program believe supportive proposed clinical development plan includes pivotal placebocontrolled efficacy study recently submitted investigational new drug application ind u fda support initiation phase trial z first half evaluating escalating dos ge protein selected dose cpg without alum different vaccination schedule plan enroll approximately subject anticipate top line immunogenicity data second half turning next tdap program investigational vaccine candidate intended active booster immunization tetanus diphtheria pertussis tdap current tdap vaccine limitation including waning effectiveness believe opportunity improve duration protection using cpg adjuvant generate thbiased immune response completed phase clinical trial adult adolescent well pertussis challenge study nonhuman primate recently received type b preind meeting feedback fda tdap clinical development regulatory pathway together result phase study nonhuman primate study feedback fda support proceeding human challenge study year plan submit ind u fda support initiation phase human challenge study tdap second half year upon completion independent study conducted canadian center vaccinology establish human challenge dose utilize phase study moving plague program collaboration funded u department defense conducting phase trial evaluating immunogenicity safety tolerability twodose plague vaccine candidate adjuvanted cpg cpg adjuvanted vaccine candidate mechanism action potential speed time protection fewer dos compared threedose alum adjuvanted vaccine previously developed department defense currently conducting randomized active controlled phase clinical trial evaluating immunogenicity safety tolerability plague vaccine candidate parallel conducting nonhuman prime challenge study expect topline data study end data inform next step program addition development program also filed supplemental bla heplisavb vaccination adult hemodialysis fda accepted pdufa action date may approved would allow u promote fourdose regimen heplisavb dialysis population look forward continuing make progress across program month ahead excited initiate next clinical trial shingle tdap program coming year turn call kelly review financial resultskelly macdonald chief financial officer thank rob pleased report another quarter full year strong financial performance review key financial result well financial guidance please note financial comparison versus prioryear period unless otherwise noted please also refer press release form k detailed financial information starting heplisavb net product revenue grew year year million another record year franchise also pleased continued trend margin profile heplisavb gross margin approximately consistent guidance mids percentage full year significant improvement compared prior year looking forward expect gross margin approximately full year consistent longterm expectation margin profile brand revenue million compared million prioryear period representing revenue related plague vaccine program collaboration funded u department defense increase primarily driven advancement nonhuman primate challenge study well continued progress throughout phase clinical contract vaccine candidate turning expense research development expense increased million compared million prioryear period increase reflecting continued advancement clinical preclinical development program selling general administrative expense million compared million prioryear period increase primarily driven higher compensation related personnel cost overall increase targeted commercial investment designed drive heplisavb market share maximize opportunity presented acips universal recommendation result generated gaap net loss million compared gaap net income million moving balance sheet ended year cash cash equivalent marketable security approximately million believe sufficient progress current pipeline asset support organic base business without need raise additional capital turning toward providing following full year financial guidance heplisavb net product revenue expected approximately million million including approximately million ex u sale commercialization agreement bavarian nordic germany expect heplisavb gross margin approximately full year expect rd expense approximately million million expect sga expense approximately million million also expect cash flow positive full year ended december reflecting continued discipline toward allocating capital drive top line revenue growth thoughtfully advancing research program closing believe strong financial profile well positioned drive sustainable growth core heplisavb business capture majority market share lead expansion adult hepatitis b vaccine market look forward progressing rd portfolio vaccine candidate continuing extremely thoughtful allocate capital accelerate growth build beyond current base business excited progress date look forward continuing deliver goal year beyond thank everyone attention today operator would like open qa portion today call question answer operatorthank operator instruction first question come line matthew phipps william blair line open matthew phipps william blair company analyst hi good afternoon thanks taking question congrats great last year wanted visit last year initially gave guidance lower something like throughout year raised subsequent update factor think drove greaterthanexpected sale initial point last year greater growth total market market share gain kind wondering factor might influence guidance go today ryan spencer chief executive officer matt thanks question think remember first full year coming reconciliation pandemic demand well acip universal recommendation one thing said think pretty clear recall prior earnings call market growth outpaced original expectation originally provided guidance earlier year also fairly successful growth market share throughout year two factor dominated better market growth originally projected matthew phipps william blair company analyst yes ok thanks right guidance year include contribution dialysis segmentryan spencer chief executive officer yes mean really provide guidance segment segment want stay true guidance year take account lot different put take year evolve going able comment one specific segmentmatthew phipps william blair company analyst ok great thanks taking question operatorthank one moment next question please next question come line jonathan miller evercore isi line openjonathan miller evercore isi analyst also congrats growth wanted drill little bit comment made little growth hep b market q still opportunity grow share q extent share growth tied overall market expansion guess secondly expectation regulatory requirement plague beyond phase nhp study year expect regulator expect dod ryan spencer chief executive officer take thanks jon thank question going donn tap first question pick second onedonn casale senior vice president commercial hey jonathan yes regarding share actually excited ability continue take market share quarter different one thing consistent around ability take market share like position ability take market share first quarter even market ryan spencer chief executive officer second question regarding plague plan regulatory plan think important know reason nonhuman primate study key part regulatory path product like utilize animal rule know yet specific path whether additional work required satisfy filing needed pathway agency rob know comment want make around plaguerobert janssen chief medical officer think covered think point know would required say eua versus full approval point ryan spencer chief executive officer data also important aspect really need see data confirm pathwayjonathan miller evercore isi analyst one gross margin said plus heplisav potential dod collaboration revenue revenue line tie could total gross margin overall gross margin still mids higherkelly macdonald chief financial officer thanks question guidance approximately full year heplisav revenue line item predominantly plague contract reimbursement carry significant margin sorry significant cost good carry cost good also yes extent continue recognizing expect continue recognizing revenue contract total company gross margin would slightly higher jonathan miller evercore isi analyst thanks muchoperatorthank one moment next question next question come line paul choi goldman sachs line open paul choi goldman sachs analyst hi good afternoon congrats strong finish u well want maybe ask thinking regard guidance think macroeconomic environment people price sensitivity sensitivity term thinking healthcare spending versus high inflation environment think maybe sort put take term demand growth course year something thinking term framing guidance followup capital allocationryan spencer chief executive officer thanks question paul guidance obviously specific market dynamic adult vaccination see macro factor big impact hepatitis b market reimbursement segment incredibly well first dollar coverage required affordable care act think good position relates macro factor continue grow vaccine market beyond paul choi goldman sachs analyst ok thanks followup know team talked bd andor partnering guess sort survey landscape sort potential bidask spread perhaps risk appetite guess partnership bd opportunity materialize let u say next month would think rank ordering capital allocation outside investing heplisav business thanks much taking questionsryan spencer chief executive officer right thanks paul yeah think appreciate highlighting fact lot flexibility identifying right asset dynavax kelly provide commentary overall capital allocation strategy kelly macdonald chief financial officer sure exceptional commercial execution heplisavb along adjuvant supply business course created strengthening financial profile certainly believe strong position help u drive growth including first foremost looking opportunity invest driving growth heplisavb well advancing organic clinicalstage asset well preclinical portfolio reflect opportunity outside ryans comment around corporate development continue evaluate strategic opportunity diversify commercial clinical product portfolio beyond certainly evaluate consider opportunity either return capital shareholder appropriate well way generate value shareholder would say sort rank ordering stand today thanks paul paul choi goldman sachs analyst great thank youoperatorthank one moment next question next question come line ernesto rodriguez dumont cowen line openernesto rodriguez dumont td cowen analyst hi everybody thanks taking question congrats great year question effect described longerthanexpected respiratory vaccine season q seasonality effect overcome q q like internally adjust estimate based second question regarding gross margin driving improvement gross margin see economy scale lower cost expecting pricing power thank youryan spencer chief executive officer yes take first one kelly handle second one far ernie thank question interpreted first part question say see q impact think rest year change update guidance mean ultimately drive one guidance number ready provide kind hard think individual factor impact like said call script know q q continue strongest quarter year continued interaction customer incredibly positive excited get respiratory season respiratory vaccine season start working customer nonrespiratory part year really drive growth market kelly handle gross margin kelly macdonald chief financial officer sure gross margin heplisavb margin improvement driven couple thing namely decreasing per unit manufacturing cost made number investment antigen manufacturing facility germany really proud way able pull improved yield time realize sort estimate approximately gross margin reiterate point made prepared remark expect gross margin range represent level consistent longterm expectation brandernesto rodriguez dumont td cowen analyst ok helpful thank youryan spencer chief executive officer thank erniekelly macdonald chief financial officer thank youoperatorthank one moment next question next question come line edward white hc wainright unknown speaker steve ed question shingle vaccine expected timing market ryan spencer chief executive officer commented longterm specificity launch obviously full clinical development program take multiple year move forward commented phase trial expectation data roll forward stephen expectation moving next study citing study looking enrollment dynamic figure exactly would able read little premature u predict specific timing filing ultimate approval provided general commentary traditional vaccine development pathway good reference point prior trial conducting space get sense time line taken studiesunknown speaker ok thank adjuvant sale year right ryan spencer chief executive officer adjuvant sale year contemplate additional adjuvant sale covid partnership time unknown speaker ok going forward ryan spencer chief executive officer unclear depends market demand market evolve individual collaborator product utilized effort put behind keeping shifting landscape including strain management obviously supportive partner initiative believe covid vaccination continue globally year come important product marketplace support neededunknown speaker right thank youoperatorthank one moment next question please next question come line roy buchanan citizen jmp line open roy buchanan jmp security analyst hey thanks taking question couple quick one plague going announce result nonhuman challenge trial phase time later year remind making cellmediated immunity assessment plague phase ii think might important thought thanksryan spencer chief executive officer take first one ask rob follow second one thing realize study funded dod data work dod partner release data release clarified yet exactly opportunity share data forum either trial need basically complete trial first roy able make top line comment like past data release plan across trial together work able provide much clarity program progressing partnership dod primary endpoint antibody rob please provide commentary around cell mediated immunity plague program robert janssen chief medical officer yeah primary endpoint looking antibody dod used previously developed vaccine particularly respect looking antibody nonhuman primate applying human looking cell mediated immune cell phase studyunknown speaker ok thank youoperatorthank time would like hand conference back mr ryan spencer closing remarksryan spencer chief executive officer thank operator thank joining u today appreciate interest dynavax excited recent accomplishment strength position overall look forward updating progress focused protecting world infectious disease operator may end call operatoroperatot signoff duration minutescall participantspaul cox vice president investor relation corporate communicationsryan spencer chief executive officerdonn casale senior vice president commercialrobert janssen chief medical officerkelly macdonald chief financial officermatthew phipps william blair company analystjonathan miller evercore isi analystpaul choi goldman sachs analysternesto rodriguez dumont td cowen analystunknown speakerroy buchanan jmp security analyst dvax analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy